New drug offers hope for rare, severe high triglyceride conditions
NCT ID NCT06796426
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program gives adults and adolescents with familial chylomicronemia syndrome (FCS) and adults with severe hypertriglyceridemia (SHTG) access to an experimental drug called plozasiran. Participants receive injections every 3 months for 15 to 21 months. The goal is to lower dangerously high triglyceride levels that standard treatments haven't controlled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
plozasiran (a drug injection)
What this could lead to
If it works, this could provide a treatment option for people with severe high triglycerides who haven't responded to standard therapy.
What could go wrong
This is an expanded access program, not a controlled trial, so results are less certain. The drug may not work for everyone and could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL CHYLOMICRONEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arrowhead Pharmaceuticals, Inc.
AVAILABLEPasadena, California, 91105, United States